logo
Leading Cause of Death in US Claims A Life Every 34 Seconds

Leading Cause of Death in US Claims A Life Every 34 Seconds

Yahoo30-01-2025

Someone dies of heart disease about every 34 seconds in the US, according to a new report, confirming the often preventable condition as the nation's leading cause of death.
"Those are alarming statistics to me – and they should be alarming for all of us, because it's likely many among those whom we lose will be our friends and loved ones," says physician Keith Churchwell, president of the American Heart Association.
The 2025 Heart Disease and Stroke Statistics Update analyzed the most recent data available, finding a total of 941,652 US deaths in 2022 from cardiovascular disease, which includes all diseases of the circulatory system.
The number of cardiac disease deaths in the 2022 CDC data was followed by the number of deaths from cancer, accidents, and then COVID-19.
"Too many people are dying from heart disease and from stroke which remains the 5th leading cause of death," continues Churchwell. "Together, they kill more people than all cancers and accidental deaths combined."
What's more, known heart disease risk factors, including high blood pressure, diabetes, and obesity continue to rise. If such trends continue hypertension and obesity will impact more than 180 million adults in the US by 2050.
In an accompanying commentary, Harvard University cardiologist Dhruv Kazi notes some of the more recent data, especially for children and adolescents, may be impacted by lifestyle changes imposed by the COVID-19 pandemic.
The comprehensive report points out that one of the biggest culprits is poor diet. Most Americans do not eat enough healthy, unprocessed foods. Heavily plant based diets like the Mediterranean or vegetarian diets are recommended for heart health.
Getting enough sleep, exercise, and managing stress and mental health all also contribute.
The report acknowledges that environmental factors, including education, income, and neighborhood availability, greatly impact food and other lifestyle choices. For example, the increasing cost of groceries can dissuade people from making healthy food choices.
As such, marginalized minority groups continue to face the greatest barriers to healthy heart choices and more heart stressors, as reflected by the heart disease outcomes.
"The age‐adjusted obesity-related cardiovascular mortality was noted to be highest among Black individuals, followed by American Indian individuals or Alaska Native individuals," the report explains.
The good news is that smoking, another major risk factor, has fallen dramatically from 42 percent of the US adult population in the 1960s to 11.5 percent.
"Excess weight now costs us even more lives than smoking – as smoking rates have actually fallen in recent years," says Stanford University cardiologist Latha Palaniappan.
Cholesterol levels have also decreased, suggesting efforts to increase awareness of the risks of high cholesterol are having some effect.
"The disparities in risk and outcomes call for tailored interventions among high-risk populations," urges Kazi. "Simply discovering breakthrough therapies isn't going to be enough – we have to ensure that these therapies are accessible and affordable to people who need them most."
The National Institute for Health recommends getting regular screening tests for heart disease from age 20, especially if you have a family history of heart conditions.
Such screening includes tests for blood pressure, cholesterol, and glucose levels.
"Although we have made a lot of progress against cardiovascular disease in the past few decades, there is a lot more work that remains to be done," says Kazi.
You can read the full report in Circulation.
Surprising Link Between Menthol And Alzheimer's Discovered in Mice
AI Can Predict Breast Cancer Risk Years Before Diagnosis, Study Finds
Microbes in Your Mouth May Impact Your Risk of Cognitive Decline

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Palantir's Collection of Disease Data at C.D.C. Stirs Privacy Concerns
Palantir's Collection of Disease Data at C.D.C. Stirs Privacy Concerns

New York Times

time40 minutes ago

  • New York Times

Palantir's Collection of Disease Data at C.D.C. Stirs Privacy Concerns

The Centers for Disease Control and Prevention's plans to consolidate data on diseases like measles and polio are raising concerns about patient privacy, delays in spotting long-term trends and ways the Trump administration may use the information. The agency told state officials earlier this week that it would shift disease information to a new system managed by Palantir, the data analysis and technology firm co-founded by Peter Thiel. The change is not entirely unexpected. The Covid pandemic revealed that the C.D.C.'s data systems were antiquated, hobbling the country's response in the crucial early months. A plan to modernize and consolidate the agency's data systems began during the Biden administration. But news that the Trump administration has expanded Palantir's work across the federal government in recent months, allowing it to compile detailed information about Americans, has introduced a new layer of anxiety and mistrust among state and local officials about sharing data with the C.D.C. Palantir's systems, including those at the C.D.C., rely on a platform called Foundry that could merge information from different agencies. The Department of Health and Human Services, the Food and Drug Administration and the National Institutes of Health all use Foundry. Some officials worry that a sprawling data collection system could expose or endanger people with sensitive health needs, like gender care, reproductive health care or disabilities. Some labor and other advocacy groups have tried to block the Trump administration from sharing data across agencies. Want all of The Times? Subscribe.

Mayor Walsh to proclaim Tourette Syndrome Awareness Day
Mayor Walsh to proclaim Tourette Syndrome Awareness Day

Yahoo

timean hour ago

  • Yahoo

Mayor Walsh to proclaim Tourette Syndrome Awareness Day

SYRACUSE. N.Y. (WSYR-TV)– Syracuse Mayor Walsh Ben has declared June 7 Tourrette Syndrome Awareness Day in Syracuse, NY. Tourette Syndrome is a neurological condition that involves involuntary, repetitive movements and vocalizations known as tics. Mayor Walsh, Councilmember Nave, families impacted by Tourette Syndrome and other Tic Disorders, and members of the Syracuse community will gather on the steps of City Hall on June 6, at noon to announce the proclamation. Recognizing the disorder will help raise awareness, educate, and promote inclusion for individuals living with Tourette Syndrome and other Tic Disorders. It will also increase supportive environments where people, regardless of their neurological disorder, can grow. According to the Centers for Disease Control and Prevention (CDC), approximately one in 50 school-aged children in the US are affected by Tourette Syndrome or a Tic Disorder, including many families in Syracuse. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Moderna Announces Update on Investigational Pandemic Influenza Program
Moderna Announces Update on Investigational Pandemic Influenza Program

Indianapolis Star

timean hour ago

  • Indianapolis Star

Moderna Announces Update on Investigational Pandemic Influenza Program

Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store